The target for the IndiTreat® mCRC Extend test is patients with metastatic colorectal cancer showing tumor progression after at least two previous lines of systemic therapy. The aim of drug treatment in these patients is not curative, but palliative, with the intention to extend survival and/or improve quality of life.
When a patient shows disease progression after having received second line of treatment, the oncologist can “re-challenge” with drugs recommended in first line (FOLFOX, FOLFIRI and FOLFOXIRI) or can treat according to drugs recommended as third line in international guidelines. ESMO guidelines recommend two options in third line: The multi-targeted kinase inhibitor regorafenib or an oral agent that combines trifluridine and tipiracil.
The treatment outcome for regorafenib is modest with an Overall Survival of 6,5 months compared to 5.1 months in the placebo arm (CORRECT study), while for trifluridine + tipiracil it is 7.1 months compared to 5.3 months in the placebo arm (RECOURSE study). These outcomes are however median values of the treatment arms, where the response of individual patients will be found within a wide range. The challenge is that there are no biomarkers to predict where in the range a specific patient response will be. Other challenges are that both treatments have considerable adverse effects and are costly.
VALUE OF GUIDED TREATMENT
The unique value of the IndiTreat® test is that the individual patient response is predicted based on tumoroids created from the patient’s own tumor cells. This is important for clinical practice, as patients not likely to respond to treatment can be spared a therapy with troublesome adverse effects. Conversely, patients likely to respond can benefit from a longer Overall Survival than the average one reported in clinical trials.
|IndiTreat® mCRC Extend – DRUG PANEL|
|Ordering Code: 2CX-01-CRC-01|
|FOLFIRI||Trifluridine + tipiracil|